Details for Patent: 9,415,016
✉ Email this page to a colleague
Which drugs does patent 9,415,016 protect, and when does it expire?
Patent 9,415,016 protects TRIJARDY XR, JENTADUETO XR, and JENTADUETO, and is included in three NDAs.
Protection for JENTADUETO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-eight patent family members in twenty-eight countries.
Summary for Patent: 9,415,016
| Title: | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
| Abstract: | The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. |
| Inventor(s): | Friedl; Thomas (Ochsenhausen, DE), Braun; Michael (Senden, DE), Egusa; Kenji (Biberach an der Riss, DE), Fujita; Hikaru (Osaka, JP), Maruyama; Megumi (Hyogo, JP), Nishioka; Takaaki (Kobe, JP) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
| Application Number: | 14/836,996 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,415,016 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Formulation; |
Drugs Protected by US Patent 9,415,016
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-001 | Jan 27, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-002 | Jan 27, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-003 | Jan 27, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-004 | Jan 27, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Boehringer Ingelheim | JENTADUETO XR | linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208026-001 | May 27, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,415,016
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 08154039 | Apr 3, 2008 | |
International Family Members for US Patent 9,415,016
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 071175 | ⤷ Sign Up | |||
| Australia | 2009232043 | ⤷ Sign Up | |||
| Brazil | PI0911273 | ⤷ Sign Up | |||
| Canada | 2720450 | ⤷ Sign Up | |||
| Chile | 2009000809 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
